马昔腾坦在中国真实世界临床实践中治疗肺动脉高压患者的有效性和安全性
[Translation] Efficacy and safety of macitentan in the treatment of patients with pulmonary arterial hypertension in real-world clinical practice in China
肺动脉高压是一种进行性、衰弱性疾病,由肺血管张力增高和血管重塑引起。近期的研究证据表明,内皮素受体拮抗剂(ERA)是治疗 PAH 的有效药物。马昔腾坦是第二代 ERA,可发挥肺血管扩张作用,且不会导致在既往 ERA 中观察到的显著副作用。2017 年,马昔腾坦被国家药品监督管理局批准用于治疗 PAH。本研究目的在于评价马昔腾坦在中国肺动脉高压成人患者中的有效性和安全性。
[Translation] Pulmonary hypertension is a progressive, debilitating disease caused by increased pulmonary vascular tone and vascular remodeling. Recent research evidence suggests that endothelin receptor antagonists (ERAs) are effective drugs for the treatment of PAH. Macitentan is a second-generation ERA that exerts pulmonary vasodilator effects without causing the significant side effects observed with previous ERAs. In 2017, macitentan was approved by the National Medical Products Administration for the treatment of PAH. The purpose of this study was to evaluate the effectiveness and safety of macitentan in Chinese adult patients with pulmonary hypertension.
100 Clinical Results associated with Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd.
0 Patents (Medical) associated with Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd.
100 Deals associated with Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd.
100 Translational Medicine associated with Actelion Pharmaceuticals Trading (Shanghai) Co. Ltd.